Patients with opioid use disorder treated with either methadone or buprenorphine are at risk of developing central sleep apnea (CSA) from these medications. Investigators will conduct a mechanistic trial using acetazolamide, a medicine known to improve CSA in other settings, to determine if acetazolamide can improve CSA due to medication for opioid use disorder and whether this leads to physiologic changes that might lead to reduced drug craving. Patients treated with medication for opioid use disorder and who have central sleep apnea will be randomized to treatment with acetazolamide or matching placebo for 7 days. At the end of the 7 days, they will undergo an overnight sleep study to assess the impact on breathing during sleep as well as sleep quality. In addition, measures of sympathetic tone, anxiety, arousal, cognition, and drug craving will be measured to determine if treatment of CSA with acetazolamide can produce physiologic changes that might contribute to improved health.

Start Date01 Mar 2025

Sponsor / Collaborator

University of Pittsburgh

[+1]

NCT03806751

/ WithdrawnEarly Phase 1IIT

A Noninvasive Arterial Input Estimation Method for O-15 PET and Integrated PET/MR Scanning

The overall aim of this project is to implement a non-invasive method of measuring quantitative regional cerebral blood flow (rCBF) on the UAB hybrid PET/MRI scanner to allow conducting such [O-15]water based scans with relative ease and safety in a large variety of important clinical and research applications. Participants will undergo imaging at baseline and after administration of a drug to increase cerebral blood flow to evaluate perfusion estimates during low and high flow states. The goal of this study is to generate data that will justify eliminating invasive arterial sampling in most [O-15]water-based PET protocols.

Start Date01 Feb 2025

Sponsor / Collaborator

The University of Alabama at Birmingham

NCT06776432

/ RecruitingPhase 2

A Phase 2A Double-Blind Randomized, Controlled, Dose Escalation, Parallel- Arm, Safety and Efficacy Study of Sivopixant, Acetazolamide and SASS-001 in Sleep Apnea

The primary purpose of this study is to evaluate the effectiveness of sivopixant, acetazolamide and SASS-001 in adults with sleep apnea with a central component.

Start Date01 Feb 2025

Sponsor / Collaborator

Shionogi-Apnimed Sleep Science LLC

100 Clinical Results associated with Acetazolamide

100 Translational Medicine associated with Acetazolamide

100 Patents (Medical) associated with Acetazolamide

10,642

Literatures (Medical) associated with Acetazolamide

31 Dec 2025·Pulmonology

Early effects of acetazolamide on hemoglobin mass and plasma volume in chronic mountain sickness at 5100 m

Article

Author: Hancco, I. ; Stauffer, E. ; Robach, P. ; Howe, C.A. ; Pina, A. ; Doutreleau, S. ; Champigneulle, B. ; Verges, S. ; Pichon, A. ; Brugniaux, J.V. ; Connes, P. ; Salazar-Granara, A.A. ; Guergour, D.

INTRODUCTION AND OBJECTIVESChronic Mountain Sickness (CMS) syndrome, combining excessive erythrocytosis and clinical symptoms in highlanders, remains a public health concern in high-altitude areas, especially in the Andes, with limited therapeutic approaches. The objectives of this study were to assess in CMS-highlanders permanently living in La Rinconada (5100-5300 m, Peru, the highest city in the world), the early efficacy of acetazolamide (ACZ) and atorvastatin to reduce hematocrit (Hct), as well as the underlying mechanisms focusing on intravascular volumes.MATERIALS AND METHODSForty-one males (46±8 years of age) permanently living in La Rinconada for 15 [10-20] years and suffering from CMS were randomized between ACZ (250 mg once-daily; N = 13), atorvastatin (20 mg once-daily; N = 14) or placebo (N = 14) uptake in a double-blinded parallel study. Hematocrit (primary endpoint) as well as arterial blood gasses, total hemoglobin mass (Hb_mass) and intravascular volumes were assessed at baseline and after a mean (±SD) treatment duration of 19±2 days.RESULTSACZ increased PaO₂ by +13.4% (95% CI: 4.3 to 22.5%) and decreased Hct by -5.2% (95% CI: -8.3 to -2.2%), whereas Hct remained unchanged with placebo or atorvastatin. ACZ tended to decrease Hb_mass (-2.6%, 95% CI: -5.7 to 0.5%), decreased total red blood cell volume (RBCV, -5.3%, 95% CI: -10.3 to -0.3%) and increased plasma volume (PV, +17.6%, 95% CI: 4.9 to 30.3%). Atorvastatin had no effect on intravascular volumes, while Hb_mass and RBCV increased in the placebo group (+6.1%, 95% CI: 4.2 to 7.9% and +7.0%, 95%CI: 2.7 to 11.4%, respectively).CONCLUSIONSShort-term ACZ uptake was effective to reduce Hct in CMS-highlanders living at extreme altitude >5,000 m and was associated with both an increase in PV and a reduction in RBCV.

31 Dec 2025·Pulmonology

High altitudes and partial pressure of arterial oxygen in patients with chronic obstructive pulmonary disease - A systematic review and meta-analysis

Review

Author: Furian, M. ; Gaisl, T. ; Bloch, K.E. ; Forrer, A. ; Lichtblau, M. ; Graf, L. ; Sevik, A. ; Ulrich, S.

IMPORTANCEPrior study in healthy subjects has shown a reduction of partial pressure of arterial oxygen (PaO₂) by -1.60 kPa/kilometre of altitude gain. However, the association of altitude-related change in PaO₂ and altitude-related adverse health effects (ARAHE) in patients with chronic obstructive pulmonary disease (COPD) remain unknown.OBJECTIVETo provide an effect size estimate for the decline in PaO₂ with each kilometre of altitude gain and to identify ARAHE in relation to altitude in patients with COPD. www.crd.york.ac.uk/prospero: CRD42020217938.DATA SOURCESA systematic search of PubMed and Embase was performed from inception to May 30, 2023.STUDY SELECTIONPeer-reviewed and prospective studies in patients with COPD staying at altitudes >1500 m providing arterial blood gases within the first 3 days at the target altitude.DATA EXTRACTION AND SYNTHESISAggregate data (AD) on study characteristics were extracted, and individual patient data (IPD) were requested. Estimates were pooled using random-effects meta-analysis.MAIN OUTCOME AND MEASURESRelative risk estimates and 95 % confidence intervals for the association between PaO₂ and altitude in patients with COPD.RESULTSThirteen studies were included in the AD analysis, of which 6 studies (222 patients, 45.2 % female) provided IPD, thus were included in the quantitative analysis. The estimated effect size of PaO₂ was -0.84 kPa [95 %CI, -0.92 to -0.76] per 1000 m of altitude gain (I²=65.0 %, P < 0.001). In multivariable regression analysis, COPD severity, baseline PaO₂, age and time spent at altitude were predictors for PaO₂ at altitude. Overall, 37.8 % of COPD patients experienced an ARAHE, whereas older age, female sex, COPD severity, baseline PaO_2, and target altitude were predictors for the occurrence of ARAHE (area under ROC curve: 0.9275, P < 0.001).CONCLUSIONS AND RELEVANCEThis meta-analysis, providing altitude-related decrease in PaO₂ and risk of ARAHE in patients with COPD ascending to altitudes >1500 m, revealed a lower altitude-related decrease in PaO₂ in COPD patients compared with healthy. However, these findings might improve patient care and facilitate decisions about initiating preventive measures against hypoxaemia and ARAHE in patients with COPD planning an altitude sojourn or intercontinental flight, i.e. supplemental oxygen or acetazolamide.

01 Dec 2025·Child's Nervous System

Cranial vault expansion in treatment of paediatric idiopathic intracranial hypertension

Article

Author: Cuthbert, Hadleigh ; Afshari, Fardad T ; Solanki, Guirish A ; Jagadeesan, Jagajeevan ; Parida, Amitav ; Rodrigues, Desiderio

INTRODUCTIONIdiopathic intracranial hypertension (IIH) is a rare clinical entity in the paediatric population. Clinical presentation is mostly similar to adult counterpart and can include headaches, vomiting, papilloedema, deterioration in visual acuity or fields, and 6th cranial nerve palsy, leading to significant morbidity. Therapeutic lumbar puncture and medical treatment with acetazolamide are usually the first-line treatments. In a minority of refractory cases, particularly where visual function is threatened, CSF diversion has been traditionally used in clinical practice. CSF diversion in IIH patients can be associated with high rate of shunt malfunction and revision due to small ventricular size leading to repeated procedures. We describe our experience with cranial vault expansion as a method of treatment of paediatric IIH cases refractory to medical treatment as a CSF diversion sparing method.METHODSFollowing review of IIH cases undergoing surgical treatment in our unit over 15 years (years 2009-2024), cases receiving cranial vault expansion as primary surgical treatment were selected and further analysed. Inclusion criteria were paediatric cases (age < 16) undergoing vault expansion as first surgical treatment for IIH refractory to pharmacological treatment for vision-threatening papilloedema. All cases were discussed within multidisciplinary meeting and selected following consideration of all management options.RESULTSOver the studied period, we identified two cases of refractory IIH with severe papilloedema undergoing cranial vault expansion as primary shunt-sparing surgery. Both patients presented with symptoms of headaches, vomiting, and blurred vision with ophthalmological confirmation of severe papilloedema despite pharmacological therapy. Following multidisciplinary discussions, both underwent successful supratentorial vault expansion. Pharmacological treatment was discontinued in both cases following surgery. Evaluation at latest follow-up showed resolution of symptoms and papilloedema with no need for subsequent cerebrospinal fluid diversion at the latest follow-up.CONCLUSIONCranial vault expansion is a viable and safe alternative surgical option in paediatric IIH cases refractory to medical treatment obviating the need for repeated shunt procedures. In cases with extremely small ventricles or where parental choice precludes CSF diversion, cranial vault expansion can be considered.

News (Medical) associated with Acetazolamide

03 Sep 2024

·www.businesswire.com

Obsidian Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for OBX-115 for the Treatment of Advanced Melanoma

CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Obsidian Therapeutics, Inc. , a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to OBX-115 for the treatment of patients with unresectable or metastatic melanoma that is resistant to immune checkpoint inhibitor (ICI) therapy. OBX-115 is a novel engineered tumor-derived autologous T cell immunotherapy (tumor-infiltrating lymphocyte [TIL] cell therapy) armored with membrane-bound IL15 (mbIL15) that is pharmacologically regulated using FDA-approved small molecule drug acetazolamide. This second FDA designation follows a July 2024 announcement of Fast Track designation for OBX-115. “RMAT designation for OBX-115 highlights the unmet need in ICI-resistant melanoma and OBX-115’s potential to provide patient-centric, transformative care in this setting,” said Parameswaran Hari, M.D., Chief Development Officer of Obsidian. “In an oral presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, initial Phase 1 data showed that OBX-115 exhibited a favorable safety profile relative to what has been observed historically from IL2-dependent non-engineered TIL cell therapy, encouraging efficacy in patients with heavily pre-treated disease, and compatibility with non-surgical core needle biopsy tumor tissue procurement . We look forward to continued collaborative interaction with the FDA as we advance OBX-115 clinical development in both melanoma and non-small cell lung cancer (NSCLC).” Established under the 21st Century Cures Act, RMAT designation is a dedicated program that includes the benefits of Fast Track and Breakthrough Therapy designations and is designed to expedite the development and review processes for certain promising drug candidates, including cell therapies. An investigational cell therapy is eligible for RMAT designation if it meets the definition of regenerative medicine therapy, is intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the therapy has the potential to address unmet medical needs for that disease. RMAT designation provides early and frequent interactions with the FDA, including intensive guidance on efficient drug development. Candidates receiving RMAT designation may also be eligible for Accelerated Approval and Priority Review. About OBX-115 Obsidian’s lead investigational cytoTIL15™ program, OBX-115, is a novel engineered tumor-derived autologous T cell immunotherapy (tumor-infiltrating lymphocyte [TIL] cell therapy) armored with pharmacologically regulatable membrane-bound IL15 (mbIL15). OBX-115 has the potential to become a meaningful therapeutic option for patients with advanced or metastatic melanoma and other solid tumors by leveraging the expected benefits of mbIL15 and Obsidian’s proprietary, differentiated manufacturing process to enhance persistence, antitumor activity, and clinical safety of TIL cell therapy. Obsidian is investigating OBX-115 in a multicenter trial in patients with advanced melanoma or relapsed / refractory NSCLC ( NCT06060613 ). About Obsidian Therapeutics Obsidian Therapeutics, Inc. is a clinical-stage biotechnology company pioneering engineered cell and gene therapies to deliver transformative outcomes for patients with intractable diseases. Obsidian’s proprietary cytoDRiVE® technology is designed to precisely regulate the timing and level of protein function by using FDA-approved small-molecule drugs. Obsidian is headquartered in Cambridge, MA. The Company has collaborations with Bristol Myers Squibb and Vertex Pharmaceuticals. For more information, please visit www.obsidiantx.com and follow us on LinkedIn.

Cell TherapyImmunotherapyFast TrackPhase 1ASCO

03 Jun 2024

·www.biospace.com

Obsidian Therapeutics Announces Additional OBX-115 Safety and Efficacy Data in Oral Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

OBX-115 continues to demonstrate a positively differentiated safety pro to IL2-dependent non-engineered TIL cell therapy: no DLTs, no Grade 4 or higher non-hematologic TEAEs observed. OBX-115 efficacy pro in additional patients, including a 44% ORR with 2 CRs (n=9), and a 50% ORR in patients receiving cell dose >30 × 109 cells. Emerging survival and PFS data are promising, with no treatment- or disease-related mortality (OS 100%, median study follow-up of 29.5 weeks) and PFS of 75% at 24 weeks. CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Obsidian Therapeutics Inc., a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced updated data from the ongoing Phase 1 first-in-human, dose-escalation study of OBX-115, a novel engineered tumor-derived autologous T-cell immunotherapy (tumor-infiltrating lymphocyte [TIL] cell therapy) armored with pharmacologically regulatable membrane-bound IL15 (mbIL15), in patients with immune checkpoint inhibitor (ICI)-resistant advanced or metastatic melanoma. These data were presented in an oral presentation delivered by Rodabe Amaria, M.D., professor of Melanoma Medical Oncology at The University of Texas MD Anderson Cancer Center and principal investigator of the study, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. The oral presentation for the single-center study (NCT05470283) included a 3-month incremental data update (relative to published abstract) on safety (N=10) and efficacy (n=9 per-protocol efficacy analysis set) for patients with advanced or metastatic melanoma. Summary of OBX-115 Safety and Efficacy Data (April 4, 2024 data cutoff): OBX-115 Exhibits Positively Differentiated Safety Pro to IL2-Dependent Non-Engineered TIL Cell Therapy: All 10 infused patients were alive at data cutoff (median study follow up of 29.5 weeks). No patient received care in the intensive care unit. No dose-limiting toxicities were observed at any dose level. No Grade 4 or higher non-hematologic treatment-emergent adverse events (TEAEs) were reported; 2 patients experienced limited Grade 3 non-hematologic TEAEs. No confirmed events of cytokine release syndrome, capillary leak syndrome, or immune effector cell-associated neurotoxicity syndrome were reported. OBX-115 Sustains Consistent Efficacy Profile, without IL2 Administration, in Patients with Substantially Pre-Treated Resistant/Refractory Disease: Patients had disease that was predominantly ICI primary-resistant, with a median of 3.5 (range, 1–6) lines of prior systemic therapy, including a median of 2 (1–3) lines of prior ICI therapy. 44% objective response rate (ORR), including 2 complete responses (CRs), using investigator-assessed RECIST 1.1 criteria across all doses (n=9 per-protocol efficacy analysis set). 50% ORR in patients who received OBX-115 dose of >30 × 109 cells (n=6). 100% disease control, defined as CR, PR, or ≥12-week duration of stable disease post OBX-115 infusion. Progression-free survival (PFS) was 75% at 24 weeks. Tumor burden reduction in all 9 patients, including several with tyrosine kinase inhibitor (TKI)-refractory disease and / or prior treated brain metastasis. Disease control and responses observed with both fresh and cryopreserved OBX-115 product. Additional OBX-115 Data Contributing to an Optimized Cell Therapy Product: Robust manufacturing process observed for OBX-115, including from tumor tissue obtained using core needle biopsy. Median manufactured OBX-115 dose (N=10): 100 × 109 cells. Translational data highlight that the OBX-115 infusion product is optimized for response and persistence: predominantly CD8+ cytotoxic T-cell population, effector memory phenotype, high proportion of CD8+CD39-CD69- (double-negative) “stem-like” progenitor cells and low levels of exhaustion markers. Dr. Amaria commented, “OBX-115 continues to demonstrate positive safety and efficacy data in additional patients, which is encouraging, given this is a heavily pre-treated patient population with advanced disease. Unfortunately, late-line systemic therapy options offer limited benefit, with ORR of approximately 10% and mPFS of approximately 2–3 months. It is exciting to see a potential new option emerge for these patients with a positively differentiated safety pro promising early activity achieved without IL2.” “We believe OBX-115 has the potential to advance the TIL cell therapy field in multiple ways, including enabling non-surgical tumor tissue procurement and abrogating the need for IL2. We are also exploring the ability to re-energize engrafted OBX-115 cells with acetazolamide re-dosing,” commented Parameswaran Hari, M.D., Chief Development Officer of Obsidian. “We look forward to continuing to build on this momentum and apply key learnings from the first-in-human Phase 1 study to our ongoing Phase 1/2 multicenter study, where we are continuing to explore these attributes and optimize the OBX-115 regimen in melanoma and non-small cell lung cancer.” Obsidian is actively enrolling patients with advanced or metastatic melanoma and non-small cell lung cancer (NSCLC) at multiple sites in its ongoing Phase 1/2 multicenter study. Additional details may be found at clinicaltrials.gov, using identifier: NCT06060613. About OBX-115 Obsidian’s lead investigational cytoTIL15™ program, OBX-115, is a novel engineered tumor-derived autologous T cell immunotherapy (tumor-infiltrating lymphocyte [TIL] cell therapy) armored with pharmacologically regulatable membrane-bound IL15 (mbIL15). OBX-115 has the potential to become a meaningful therapeutic option for patients with advanced or metastatic melanoma and other solid tumors by leveraging the expected benefits of mbIL15 and Obsidian’s proprietary, differentiated manufacturing process to enhance persistence, antitumor activity, and clinical safety of TIL cell therapy. OBX-115 is being investigated in two ongoing clinical trials in advanced or metastatic melanoma and NSCLC (NCT05470283 and NCT06060613). About Obsidian Therapeutics Obsidian Therapeutics, Inc. is a clinical-stage biotechnology company pioneering engineered cell and gene therapies to deliver transformative outcomes for patients with intractable diseases. Obsidian’s proprietary cytoDRiVE® technology is designed to precisely regulate the timing and level of protein function by using FDA-approved small-molecule drugs. Obsidian is headquartered in Cambridge, MA. The Company has collaborations with Bristol Myers Squibb and Vertex Pharmaceuticals. For more information, please visit obsidiantx.com and follow us on LinkedIn.

Clinical ResultPhase 1Cell TherapyASCOImmunotherapy

04 Apr 2024

·www.pharmaceutical-technology.com

Obsidian raises $160.5m to advance TIL cell therapy programme

TIL therapy uses naturally occurring immune cells that detect and attack cancer cells. Image credit: Shutterstock/Christoph Burgstedt. Obsidian Therapeutics has raised $160.5m in a Series C financing round, with plans for the funds to be injected into the biotech’s tumour-infiltrating lymphocyte (TIL) cell therapy programme. Obsidian, already backed by Bristol Myers Squibb (BMS), added Novo Nordisk Foundation’s investment arm Novo Holdings to its arsenal of investors in this latest round. US investment firm Wellington Management led the oversubscribed Series C. The US biotech previously raised $115m in a Series B round in 2021. Obsidian’s lead asset is OBX-115 , which is part of its TIL programme. OBX-115 is a TIL cell therapy – which expands and enhances the patient’s own immune cells extracted from around and within the tumour itself. Unlike the emerging chimeric antigen receptor (CAR) T cell therapies , TILs already have multiple tumour target recognition. The T cell immunotherapy is in a Phase I clinical trial for the treatment of melanoma and a Phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC). In the melanoma trial (NCT05470283), which is being sponsored by the MD Anderson Cancer Centre, OBX-115 is being administered in combination with the diuretic acetazolamide. Data from the study will inform dose levels for a Phase II trial. The company reported an objective response rate of 50% and a complete response rate of 33% in topline data released in December 2023. See Also: Seaport emerges after $100m raise with ex-Karuna team at helm Pluri launches manufacturing division as cell therapy pipeline progresses The NSCLC trial (NCT06060613) is investigating OBX-115 as a monotherapy, with endpoints assessing the drug’s safety and efficacy in treating advanced solid tumours. Obsidian said the Series C proceeds will go towards clinical trial activities and manufacturing scale-up with a view to conducting pivotal trials. Obsidian has engineered OXB-115 such that it produces the membrane-bound interleukin 15 (IL-15). Interleukin-2 (IL-2) co-administration is usually needed with traditional TIL cell therapies to act as an immunostimulatory agent. Obsidian states that the membrane-bound IL-15 could widen patient access by reducing potential toxicities associated with high-dose IL-2. Vertex and BMS have seen the potential in Obsidian’s platform, both signing multi-year partnerships with the biotech to discover and develop new cell therapies. Last month, Iovance Biotherapeutics ’ Amtagvi (lifileucel) became the first TIL cell therapy to get regulatory backing in the US, winning a US Food and Drug Administration (FDA) accelerated approval. Obsidian’s OBX-115 will face competition from Iovance, with Amtagvi indicated for the treatment of metastatic or unresectable melanoma. Iovance has priced its immunotherapy at $515,000 in a market where there are currently no other FDA-approved cell therapies for the treatment of solid tumours. Amtagvi is forecast to generate sales of $846m by 2029, according to GlobalData’s Pharma Intelligence Centre. GlobalData is the parent company of Pharmaceutical Technology. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content. Free Whitepaper Cell and gene therapies: Pipe dream to pipeline The cell and gene industry is gaining momentum, with a new wave of therapies promising to transform the way doctors treat, and even cure, disease. In this report, Cytiva and GlobalData have collaborated to explore the rise of the cell and gene therapy industries, the current state of the market, present and future opportunities for advancement, and the challenges that lie ahead. By Cytiva Thematic By downloading this case study, you acknowledge that GlobalData may share your information with Cytiva Thematic and that your personal data will be used as described in their Privacy Policy

Cell TherapyPhase 1ImmunotherapyClinical ResultGene Therapy

100 Deals associated with Acetazolamide

External Link

KEGG	Wiki	ATC	Drug Bank
D00218	Acetazolamide	S01EC01	DB00819

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Acute angle-closure glaucoma	Australia	Phebra Pty Ltd.	01 Jun 2009
Glaucoma, Open-Angle	Australia	Phebra Pty Ltd.	01 Jun 2009
Secondary glaucoma	Australia	Phebra Pty Ltd.	01 Jun 2009
Pre-Eclampsia	Japan	Sanwa Kagaku Kenkyusho Co., Ltd.	02 Jun 1994
Sleep Apnea Syndromes	Japan	Sanwa Kagaku Kenkyusho Co., Ltd.	29 Mar 1988
Ocular Hypertension	China	Tianjin Lisheng Pharmaceutical Co., Ltd.	01 Jan 1983
Acidosis, Respiratory	Japan	Sanwa Kagaku Kenkyusho Co., Ltd.	29 Mar 1955
Edema	Japan	Sanwa Kagaku Kenkyusho Co., Ltd.	29 Mar 1955
Epilepsy	Japan	Sanwa Kagaku Kenkyusho Co., Ltd.	29 Mar 1955
Glaucoma	Japan	Sanwa Kagaku Kenkyusho Co., Ltd.	29 Mar 1955
Meniere Disease	Japan	Sanwa Kagaku Kenkyusho Co., Ltd.	29 Mar 1955
Premenstrual Syndrome	Japan	Sanwa Kagaku Kenkyusho Co., Ltd.	29 Mar 1955

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Glaucoma	Preclinical	China	Ocumension （Hong Kong） Limited	30 Jun 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04639193 (RESCUE-Combo, Pubmed \| Ann Am Thorac Soc)	Phase 2	Sleep Apnea, Obstructive	20	Acetazolamide+eszopiclone	ncobbndpcb(jwnqfjpdto) = qotldldbmt yjfdtzvmed (dzomxofkyo, -24.1 to -5.2)	Positive	08 Nov 2024
NCT03505788 (ADVOR trial \| Advor, CTgov)	Phase 4	Volume overload \| Metabolic Diseases \| Acute decompensated heart failure	519	placebo (Placebo)	sigcbgurbk(mrvzpvhypf) = ocgahdqyda khtfmgwoov (hkoeifmppo, osvfpgoyyi - gdlehbnhrg) View more	-	28 Oct 2024
				Acetazolamide (Acetazolamide)	sigcbgurbk(mrvzpvhypf) = wymvlqujov khtfmgwoov (hkoeifmppo, jtxwjlhimn - xntspauauj) View more
NCT05473364 (Acetazolamide in Persons with Type 1 Diabetes, Pubmed \| J Am Soc Nephrol)	Phase 1	Diabetes Mellitus, Type 1	12	Acetazolamide 62.5 mg	pltygemkja(kzdojdmluj) = nfcdgdgham detmkgnrcc (hmwtnqiosi ) View more	Positive	08 Oct 2024
				Acetazolamide 125 mg	pltygemkja(kzdojdmluj) = lgnlwklntb detmkgnrcc (hmwtnqiosi ) View more
NCT03505788 (ADVOR Trial, Pubmed \| Circ Heart Fail)	Phase 4	Volume overload \| Heart Failure Add-on serum chloride	519	Acetazolamide	tlrwjwsjmm(imhonnsggo) = Hypochloremia is associated with diuretic resistance and worse clinical outcomes susncikffm (znaygjymos )	Positive	01 Oct 2024
				Placebo
EURETINA2024 Manual	Not Applicable	Macular Edema	7	acetazolamidement (acetazolamide and localized anti-inflammatory agents)	(ltjjcdpfzc) = gbliabnekp xutndkavpm (jmexnsnwll )	Positive	19 Sep 2024
				Anti-vascular endothelial growth factor (anti-VEGF) injections	(ltjjcdpfzc) = jvivdyoien xutndkavpm (jmexnsnwll )
ESC2024	Not Applicable	Acute decompensated heart failure	-	Acetazolamide plus standard of care (SOC)	rqepyscklx(oxlnwstsja): RR = 1.36 (95% CI, 1.1 - 1.68), P-Value = 0.005	-	02 Sep 2024
				Standard of care (SOC) alone
ESC2024	Not Applicable	Acute decompensated heart failure	-	Acetazolamide-use	qylcfvimrn(oqqhfiscgu) = luvopkqcxr uotwnmqlyh (gbcgejzjbw ) View more	-	31 Aug 2024
				acetazolamide (No-use)	qylcfvimrn(oqqhfiscgu) = qsytwmobai uotwnmqlyh (gbcgejzjbw ) View more
NCT03505788 (ADVOR, ESC2024)	Phase 4	Volume overload \| Heart Failure Add-on serum chloride	519	Acetazolamide	wajqjzbfnz(guzbjnqqrd) = dnxeeyookd nkduhlzjrh (ljvutxjqqd ) View more	Positive	14 May 2024
				Placebo	wajqjzbfnz(guzbjnqqrd) = dbuqoxqaqy nkduhlzjrh (ljvutxjqqd ) View more
NCT04639193 (RESCUE-Combo, CTgov)	Phase 2	Sleep Apnea, Obstructive	20	Acetazolamide+Eszopiclone (Dual-Therapy)	(lwuzlbensd) = umkyofbfvk dxkjlvdjlp (wihqoptadg, vpkgzdmmvq - kwrdaadgsa) View more	-	02 May 2024
				Placebo+Acetazolamide+Eszopiclone (Placebo)	(lwuzlbensd) = jkzokezauk dxkjlvdjlp (wihqoptadg, anbahtnbwr - nrgxjvxkuy) View more
NCT05470283 (AACR2024) Manual	Phase 1	Metastatic melanoma	6	OBX-115 + ACZ 125 mg	(fxgpuqqbjl) = clnqengqav fljozxwwwb (fvguzhjolz ) View more	Positive	05 Apr 2024

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis